Buradasınız

Anasayfa » Content

Olmesartana Bağlı Anjiyoödem, Anjiyotensin Dönüştürücü Enzim İnhibisyonu ve Kinin Peptidazlar Tarafından Tetiklenir mi? Nadir Bir Olgu

Is Olmesartan-Induced Angioedema Triggered by Angiotensin Converting Enzyme Inhibition and Kinin Peptides? A Rare Case

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2014
DOI: 
10.5262/tndt.2014.1003.16

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Olmesartan medoxomil (OM) is an angiotensin II receptor blocker (ARB) and it is used for the treatment of hypertension. Among all ARB drugs, only OM shows an angiotensin converting enzyme inhibitory effect (ACEI). OM may cause angioedema by its ARB effect. It can exhibit this role by the endogenous ACEI effect. While the frequency of angioedema associated with ACEI ranges from 0.1% to 1%, the frequency of ARB-induced angioedema is reported to range from 0.1% to 0.4%. A 38-year-old woman was diagnosed with primary hypertension and 20 mg/day OM was started for the management of hypertension. Following the second day of OM treatment, she was admitted to the emergency department because of a new episode of acute angioedema of the tongue, face and lips. OM induced angioedema was diagnosed. OM therapy was switched to a calcium channel blocker.
Bookmark/Search this post with
Abstract (Original Language): 
Olmesartan medoxomil (OM), anjiyotensin II reseptör blokeridir (ARB) ve hipertansiyon tedavisi için kullanılır. Tüm ARB’ler arasında sadece OM’nin anjiyotensin dönüştürücü enzim inhibitörü (ADEİ) etkisi vardır. OM, ARB etkisi ile anjiyoödeme neden olur. Bu rolü endojen ADEİ etkisi sayesinde yapar. ADEİ alımından sonra anjiyoödem sıklığı %0,1 ile %1-5 arasında bulunmasına rağmen, ARB’lerin neden olduğu anjiyoödemin %0,1 ile %0,4-6 arasında olduğu bildirilmektedir. 38 yaşında kadın hastaya primer hipertansiyon teşhisi kondu. Hipertansiyon tedavisi için 20 mg/gün OM tedavisi planlandı. Hasta, OM’nin ikinci gününde dudak, yüz ve dilde meydana gelen akut anjiyoödem nedeniyle hastanemiz acil servise başvurdu. OM’nın neden olduğu anjiyoödem teşhisi kondu ve bu nedenle OM tedavisi kalsiyum kanal blokeri ile değiştirildi.
FULL TEXT (PDF): 
PDF icon arastirmax-olmesartana-bagli-anjiyoodem-anjiyotensin-donusturucu-enzim-inhibisyonu-kinin-peptidazlar-tarafindan-tetiklenir-mi-nadir-bir-olgu.pdf
  • 3
262
264
  • Turkish

REFERENCES

References: 

1. Zuraw BL, Christiansen SC: Pathophysiology of hereditary
angioedema. Am J Rhinol Allergy 2011;25:373-378
2. Bas M, Hoffmann TK, Kojda G, Bier H: ACE-inhibitor induced
angioedema. Laryngorhinootologie 2007;86:804-808
3. Molinaro G, Cugno M, Perez M, Lepage Y, Gervais N, Agostoni
A, Adam A: Angiotensin-converting enzyme inhibitor-associated
angioedema is characterized by a slower degradation of desarginine(
9)-bradykinin. J Pharmacol Exp Ther 2002;303:232-237
4. Caldeira D, David C, Sampaio C: Tolerability of angiotensinreceptor
blockers in patients with intolerance to angiotensinconverting
enzyme inhibitors: A systematic review and metaanalysis.
Am J Cardiovasc Drugs 2012;12:263-2775. Vasquez JL, Jaramillo JC, Fernandez C, Enriquez A, Mielgo R:
Severe angioedema associated with olmesartan. Ann Allergy
Asthma Immunol 2011;107:285
6. Bouer IH, Reams GP, Wu Z, Lau-Sieckman A: Effects of losartan
on the renin-angiotensin-aldosterone axis in essential hypertension.
J Hum Hypertens 1995;9: 237-243
7. Campbell DJ, Krum H, Esler MD: Losartan increases bradykinin
levels in hypertensive humans. Circulation 2005;111:315-320
8. Ichikawa S, Takayama Y: Long-term effects of olmesartan, an Ang
II receptor antagonist, on blood pressure and the renin-angiotensinaldosterone
system in hypertensive patients. Hypertens Res
2001;24:641-646
9. Agata J, Ura N, Yoshida H, Shinshi Y, Sasaki H, Hyakkoku M,
Taniguchi S, Shimamoto K: Olmesartan is an angiotensin II receptor
blocker with an inhibitory effect on angiotensin-converting enzyme.
Hypertens Res 2006;29:865-874
10. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB,
Ferrario CM: Upregulation of angiotensin-converting enzyme 2
after myocardial infarction by blockade of angiotensin II receptors.
Hypertension 2004;43: 970-976

Thank you for copying data from http://www.arastirmax.com